SAN FRANCISCO & DUBLIN–(BUSINESS WIRE)–Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, and aCGT Vector, a point-of-care cell and gene therapy-as-a-service (TaaS) company, today announced a collaboration to improve manufacturing and analytic procedures used to develop personalized cell and gene therapies for cancer patients. Through this alliance, aCGT Vector will provide its point-of-care, GMP-licensed manufacturing platform to validate Xcellbio’s core next-generation manufacturing and analytical AVATAR AI technology for use in precision cancer treatment.

We’re delighted to be working closely with the highly capable Xcellbio team in the advancement of the understanding of the tumour micro environment, a further step towards increasing cancer patient access to personalised precision medicine and solid tumour treatments.

Read the full article at

https://www.businesswire.com/news/home/20221013005453/en/Xcell-Biosciences-and-aCGT-Vector-Collaborate-to-Accelerate-Development-of-Cell-and-Gene-Therapies